Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on mast cell therapeutics, with briquilimab as its core asset. The company is working to develop and commercialize treatments for chronic urticaria and other mast-cell-related indications, while also retaining rights to use briquilimab in stem cell clearance prior to hematopoietic stem cell transplantation.

2.62

— Jasper Therapeutics, Inc.
	%
Lead biologic candidate	100% Briquilimab, the company's main monoclonal antibody program, developed for mast cell-related diseases.
Clinical development programs	0% Research, preclinical work, and clinical trials supporting briquilimab and related indications.
Licensing rights	0% Exclusive rights licensed from Amgen and Stanford University for specific uses of briquilimab.

Jasper does not yet sell commercial products; its near-term 'customers' are clinical trial participants, investigators,...

Clinical trial participantsprimary
Patients enrolled in briquilimab studies, especially chronic urticaria, to generate efficacy and safety data.
Regulatorsprimary
FDA and foreign agencies that review clinical packages and determine whether the drug can be approved.
Future specialty prescriberssecondary
Allergists, immunologists, and transplant-related clinicians who would prescribe briquilimab if approved.
Payerssecondary
Commercial and government payers that will decide coverage and reimbursement for launch.

Jasper is headquartered in the United States and currently operates as a development-stage biotech with no commercial...

•Headquartered in the United States
•Primary operating base for R&D and corporate functions
•North America is the planned first commercialization region
•Outside North America, commercialization may be partner-led
•No disclosed country revenue because there are no product sales

The company has narrowed its focus to briquilimab and chronic urticaria after halting enrollment in its asthma study...

Advance briquilimab in chronic urticariashort-term

This is the company's highest-priority asset and the main path to value creation and eventual revenue.

Preserve cash and raise capitalshort-term

The company expects continued losses and needs external funding to keep development programs running.

Prepare for commercializationmedium-term

If approved, Jasper will need sales, marketing, manufacturing, and distribution capabilities to launch briquilimab.

Jasper is a pre-revenue biotech with significant accumulated losses, negative operating cash flow, and a continuing...

critical

Clinical development failure

Briquilimab must show adequate safety and efficacy in trials before approval and commercialization are possible.

Scope: Core asset and primary value driver
Materiality: High

high

Financing risk

The company expects continued losses and may need to curtail programs if capital is unavailable.

Scope: Corporate runway and program continuity
Materiality: High

high

Regulatory risk

FDA requirements may change or additional studies may be required, delaying approval.

Scope: Approval timeline and development cost
Materiality: High

high

Commercialization and reimbursement risk

Even with approval, the company must secure pricing and payer coverage to generate meaningful sales.

Scope: Launch adoption and revenue realization
Materiality: High

high

IP and licensing dependence

The business relies on exclusive licenses for briquilimab rights and must maintain those agreements.

Scope: Core product rights
Materiality: High

Research and development accruals

Can shift quarterly operating expense and liabilities

Stock-based compensation

Raises non-cash operating expense and affects loss metrics

Warrant fair value

Can create volatility in other income/expense and equity

Impairment and write-offs

May cause one-time charges if projects are abandoned

Jasper Therapeutics, Inc.

Clinical development failure

Financing risk

Regulatory risk

Commercialization and reimbursement risk

IP and licensing dependence

GALECTIN THERAPEUTICS INC

CRISPR Therapeutics AG

CAPRICOR THERAPEUTICS, INC.

INSMED Inc

Assertio Holdings, Inc.

Century Therapeutics, Inc.